AR088535A1 - Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) - Google Patents

Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)

Info

Publication number
AR088535A1
AR088535A1 ARP120104004A ARP120104004A AR088535A1 AR 088535 A1 AR088535 A1 AR 088535A1 AR P120104004 A ARP120104004 A AR P120104004A AR P120104004 A ARP120104004 A AR P120104004A AR 088535 A1 AR088535 A1 AR 088535A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
hydrogen
aryl
receptor
Prior art date
Application number
ARP120104004A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR088535(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR088535A1 publication Critical patent/AR088535A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/42—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C07C323/44—X or Y being nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto representado por la fórmula (1), sus enantiómeros, diastereoisómeros, tautómeros, hidratos, solvatos o una sal farmacéuticamente aceptable del mismo, en donde: a es 1 y b es 0; a es 0 y b es 1; a es 1 y b es 1; R¹ es alquilo C₁₋₈ opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, heterociclo opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, arilo C₆₋₁₀ opcionalmente sustituido, cicloalquenilo C₃₋₈ opcionalmente sustituido, -NR¹¹R¹² o -OR¹³; R² es alquilo C₁₋₈ opcionalmente sustituido o arilo C₆₋₁₀ opcionalmente sustituido; R³ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido, halógeno, -COOR¹⁵, -OR¹³, -NR¹¹R¹², NO₂, heterociclo opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, arilo C₆₋₁₀ opcionalmente sustituido o cicloalquenilo C₃₋₈ opcionalmente sustituido; R⁴ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido, halógeno, -COOR¹⁵, -OR¹³, -NR¹¹R¹², NO₂, heterociclo opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, arilo C₆₋₁₀ opcionalmente sustituido o cicloalquenilo C₃₋₈ opcionalmente sustituido; R⁵ es halógeno, -CF₃ o -S(O)ₙR¹⁴; n es 0, 1 ó 2; R⁶ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido, halógeno, -COOR¹⁵, -OR¹³, -NR¹¹R¹², NO₂, heterociclo opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, arilo C₆₋₁₀ opcionalmente sustituido o cicloalquenilo C₃₋₈ opcionalmente sustituido; R⁷ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido, halógeno, -COOR¹⁵, -OR¹³, -NR¹¹R¹², NO₂, heterociclo opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, arilo C₆₋₁₀ opcionalmente sustituido o cicloalquenilo C₃₋₈ opcionalmente sustituido; R⁸ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido o arilo C₆₋₁₀ opcionalmente sustituido; R⁹ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido o arilo C₆₋₁₀ opcionalmente sustituido; R¹⁰ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido o arilo C₆₋₁₀ opcionalmente sustituido; R⁹ᵃ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido o arilo C₆₋₁₀ opcionalmente sustituido; R¹⁰ᵃ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido o arilo C₆₋₁₀ opcionalmente sustituido; R¹¹ es hidrógeno o alquilo C₁₋₈ opcionalmente sustituido; R¹² es hidrógeno o alquilo C₁₋₈ opcionalmente sustituido; R¹³ es hidrógeno o alquilo C₁₋₈ opcionalmente sustituido; R¹⁴ es hidrógeno, CF₃ o alquilo C₁₋₈ opcionalmente sustituido; R¹⁵ es hidrógeno o alquilo C₁₋₈ opcionalmente sustituido; con la condición que: a) cuando a = 1 y b = 0 entonces: R⁹ no es bencilo opcionalmente sustituido; y R¹¹ no es: un compuesto del grupo de fórmulas (2); y el compuesto de la fórmula (1) no es de las estructuras del grupo de fórmulas (3); y b) cuando a = 0 y b = 1 entonces: R¹ es OR¹³; y el compuesto de la fórmula (1) no es de la estructura de fórmula (4); y c) cuando a = 1 y b = 1 entonces: R¹¹ no es un compuesto de la fórmula (5).
ARP120104004A 2011-10-26 2012-10-25 Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) AR088535A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161551772P 2011-10-26 2011-10-26

Publications (1)

Publication Number Publication Date
AR088535A1 true AR088535A1 (es) 2014-06-18

Family

ID=47116500

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120104004A AR088535A1 (es) 2011-10-26 2012-10-25 Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)
ARP200100544A AR119698A2 (es) 2011-10-26 2020-02-27 Compuesto amida n-urea sustituida derivado de aminoácido

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200100544A AR119698A2 (es) 2011-10-26 2020-02-27 Compuesto amida n-urea sustituida derivado de aminoácido

Country Status (33)

Country Link
US (9) US8658803B2 (es)
EP (2) EP3078656B1 (es)
JP (3) JP5982001B2 (es)
KR (1) KR102051687B1 (es)
CN (2) CN106518742B (es)
AR (2) AR088535A1 (es)
AU (3) AU2012329098B2 (es)
BR (2) BR122019025505B1 (es)
CA (1) CA2853648C (es)
CL (1) CL2014001080A1 (es)
CO (1) CO6960509A2 (es)
CY (1) CY1121604T1 (es)
DK (1) DK2770989T3 (es)
ES (2) ES2708997T3 (es)
HK (1) HK1199622A1 (es)
HR (1) HRP20181934T1 (es)
HU (1) HUE040145T2 (es)
IL (3) IL232204B (es)
IN (1) IN2014DN03424A (es)
LT (1) LT2770989T (es)
MX (1) MX357737B (es)
MY (1) MY172013A (es)
PH (1) PH12019500171A1 (es)
PL (1) PL2770989T3 (es)
PT (1) PT2770989T (es)
RS (1) RS58111B1 (es)
RU (2) RU2744577C2 (es)
SG (2) SG10201903266YA (es)
SI (1) SI2770989T1 (es)
TW (1) TWI631099B (es)
UA (1) UA115043C2 (es)
WO (1) WO2013062947A1 (es)
ZA (1) ZA201403222B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
SG10201903266YA (en) 2011-10-26 2019-05-30 Allergan Inc Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
WO2014138046A1 (en) * 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
SG11201507113RA (en) * 2013-03-06 2015-10-29 Allergan Inc Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
JP6653253B2 (ja) * 2013-07-16 2020-02-26 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
TWI537251B (zh) 2013-10-09 2016-06-11 長庚大學 Ｆｐｒ１拮抗劑的衍生物及其用途
CN105705484B (zh) * 2013-11-21 2018-09-14 阿勒根公司 作为甲酰肽受体调节剂的苯基氨基甲酸酯衍生物
JP6453231B2 (ja) 2013-11-28 2019-01-16 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
BR112016027133A8 (pt) 2014-05-21 2021-06-29 Allergan Inc derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
WO2016189876A1 (en) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
JP6746614B2 (ja) * 2015-05-27 2020-08-26 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
CA2992662A1 (en) * 2015-08-05 2017-02-09 Allergan, Inc. Phenyl urea analogs as formyl peptide repceptor 1 (fpr1) selective agonists
WO2017172761A1 (en) 2016-03-28 2017-10-05 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
WO2017180323A1 (en) 2016-04-12 2017-10-19 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
CA3039455A1 (en) 2016-10-06 2018-04-12 Daiichi Sankyo Company, Limited Urea derivative
JP2020015664A (ja) * 2016-11-21 2020-01-30 宇部興産株式会社 含窒素多環式ヘテロ環誘導体
US10608869B2 (en) * 2017-03-20 2020-03-31 Nicira, Inc. Handling control-plane connectivity loss in virtualized computing environments
PL3762380T3 (pl) 2018-03-05 2022-02-21 Bristol-Myers Squibb Company Agoniści fenylopirolidynonowi receptora peptydu formylowego 2
EP4234014A1 (en) * 2022-02-28 2023-08-30 Insusense ApS Amino acid based carbamates and/or ureas for the treatment of sortilin dependent diseases

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) * 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
JP3387948B2 (ja) 1992-12-04 2003-03-17 富山化学工業株式会社 新規なフェニルアラニン誘導体またはその塩
AU667995B2 (en) * 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
HUT75308A (en) * 1993-11-05 1997-05-28 Warner Lambert Co Substituted di- and tripeptide inhibitors of protein:farnesyl transferase
JPH11171896A (ja) * 1995-09-19 1999-06-29 Kirin Brewery Co Ltd 新規ペプチド化合物およびその医薬組成物
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
AU4572999A (en) * 1998-06-18 2000-01-05 Sepracor, Inc. Tetrapeptides, analogs and peptidomimetics which bind selectively mammalian opioid receptors
US6243689B1 (en) 1998-12-29 2001-06-05 Robert G. Norton System and method for authorizing electronic funds transfer at a point of sale
AU6909300A (en) 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
WO2002068586A2 (en) * 2001-01-19 2002-09-06 The Scripps Research Institute Hiv/fiv protease inhibitors
DE50209313D1 (de) * 2001-12-12 2007-03-08 Wilex Ag Selektive arylguanidinpeptide als urokinaseinhibitoren
CA2495284A1 (en) 2002-09-05 2004-03-18 Neurosearch A/S Diarylurea derivatives and their use as chloride channel blockers
WO2004039765A1 (en) * 2002-10-31 2004-05-13 Amersham Biosciences Ab Use of urea variants as affinity ligands
ATE447586T1 (de) 2002-11-07 2009-11-15 Takeda Pharmaceutical Fprl1-liganden und deren verwendung
KR100527361B1 (ko) * 2003-04-01 2005-11-09 주식회사 프로메디텍 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN1894580A (zh) * 2003-11-07 2007-01-10 阿卡蒂亚药品公司 脂氧素受体fprl1作为一种用于鉴定能有效治疗疼痛和炎症化合物的工具
WO2005047899A2 (en) * 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
CA2550012A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same and use
GB0417802D0 (en) * 2004-08-10 2004-09-15 Novartis Ag Organic compounds
AU2005302608A1 (en) 2004-10-28 2006-05-11 Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
WO2006063113A2 (en) 2004-12-07 2006-06-15 Portola Pharmaceuticals, Inc. Ureas as factor xa inhibitors
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US7884180B2 (en) 2006-09-18 2011-02-08 Compugen Ltd Peptides which bind to G protein-coupled receptors
AR065093A1 (es) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
KR20090121832A (ko) 2008-05-23 2009-11-26 인제대학교 산학협력단 2-(2-히드록시벤조일)히드라진카르복시아미드 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를유효 성분으로 함유하는 선택적 면역 억제용 약학적 조성물
US20100035932A1 (en) 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
NZ593892A (en) * 2008-12-23 2013-11-29 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
AU2011270872A1 (en) 2010-06-24 2013-01-31 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
CA2819457A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
AU2012214265A1 (en) 2011-02-11 2013-09-05 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
WO2012174243A1 (en) 2011-06-17 2012-12-20 Allergan, Inc. D -serine for the treatment of visual system disorders
GB2494851A (en) * 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
CA2841983A1 (en) 2011-07-11 2013-01-17 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
SG10201903266YA (en) 2011-10-26 2019-05-30 Allergan Inc Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8492556B2 (en) 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
WO2013122953A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators
NZ700733A (en) 2012-04-16 2016-07-29 Allergan Inc (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
SG11201507113RA (en) 2013-03-06 2015-10-29 Allergan Inc Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
WO2014138046A1 (en) 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
JP6653253B2 (ja) 2013-07-16 2020-02-26 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体
US20150080466A1 (en) 2013-09-19 2015-03-19 Allergan, Inc. Diphenyl urea derivatives as formyl peptide receptor modulators
CN105684198B (zh) 2013-10-24 2018-08-03 丰田自动车株式会社 钠电池用正极活性物质和钠电池
CN105705484B (zh) 2013-11-21 2018-09-14 阿勒根公司 作为甲酰肽受体调节剂的苯基氨基甲酸酯衍生物
BR112016027133A8 (pt) 2014-05-21 2021-06-29 Allergan Inc derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso

Also Published As

Publication number Publication date
AR119698A2 (es) 2022-01-05
SG11201401818RA (en) 2014-05-29
DK2770989T3 (en) 2018-12-17
US9974772B2 (en) 2018-05-22
TWI631099B (zh) 2018-08-01
IL256555B (en) 2020-07-30
MX357737B (es) 2018-07-23
US20130109866A1 (en) 2013-05-02
BR112014010042A8 (pt) 2017-06-20
IN2014DN03424A (es) 2015-06-05
US20170119737A1 (en) 2017-05-04
EP3078656B1 (en) 2020-07-01
JP2014534216A (ja) 2014-12-18
AU2017251683C1 (en) 2019-11-14
US8993780B2 (en) 2015-03-31
RU2014120013A (ru) 2015-12-10
PH12019500171A1 (en) 2020-06-15
US20160235711A1 (en) 2016-08-18
RU2629205C2 (ru) 2017-08-25
BR112014010042B1 (pt) 2022-03-03
US20150148395A1 (en) 2015-05-28
MX2014005047A (es) 2015-09-04
US9579307B2 (en) 2017-02-28
CY1121604T1 (el) 2020-05-29
CO6960509A2 (es) 2014-05-30
PT2770989T (pt) 2018-12-04
RU2017129434A3 (es) 2020-10-09
UA115043C2 (uk) 2017-09-11
US9351948B2 (en) 2016-05-31
BR122019025505B1 (pt) 2022-02-22
CL2014001080A1 (es) 2014-11-14
HUE040145T2 (hu) 2019-02-28
AU2012329098A1 (en) 2014-05-22
IL232204B (en) 2018-12-31
US20240285584A1 (en) 2024-08-29
US20180228772A1 (en) 2018-08-16
AU2019264555A1 (en) 2019-12-05
US20190343804A1 (en) 2019-11-14
EP2770989B1 (en) 2018-09-05
RS58111B1 (sr) 2019-02-28
SI2770989T1 (sl) 2018-12-31
RU2744577C2 (ru) 2021-03-11
MY172013A (en) 2019-11-12
IL267659B (en) 2021-10-31
AU2017251683A1 (en) 2017-11-09
ES2708997T3 (es) 2019-04-12
LT2770989T (lt) 2018-12-10
KR102051687B1 (ko) 2019-12-17
JP6804580B2 (ja) 2020-12-23
RU2017129434A (ru) 2019-02-04
CA2853648C (en) 2023-01-24
AU2017251683B2 (en) 2019-08-15
WO2013062947A1 (en) 2013-05-02
IL267659A (en) 2019-08-29
US20220202777A1 (en) 2022-06-30
ZA201403222B (en) 2015-07-29
US8658803B2 (en) 2014-02-25
US10993931B2 (en) 2021-05-04
NZ624635A (en) 2017-01-27
IL232204A0 (en) 2014-06-30
CN106518742A (zh) 2017-03-22
CN104114164B (zh) 2016-11-16
AU2012329098B2 (en) 2017-08-03
US20140094614A1 (en) 2014-04-03
BR112014010042A2 (pt) 2017-06-13
KR20140111646A (ko) 2014-09-19
TW201331168A (zh) 2013-08-01
ES2820714T3 (es) 2021-04-22
JP5982001B2 (ja) 2016-08-31
CN106518742B (zh) 2020-01-21
PL2770989T3 (pl) 2019-01-31
EP3078656A1 (en) 2016-10-12
IL256555A (en) 2018-02-28
JP2016216497A (ja) 2016-12-22
EP2770989A1 (en) 2014-09-03
JP2019089849A (ja) 2019-06-13
US10172832B2 (en) 2019-01-08
CA2853648A1 (en) 2013-05-02
HK1199622A1 (en) 2015-07-10
CN104114164A (zh) 2014-10-22
SG10201903266YA (en) 2019-05-30
HRP20181934T1 (hr) 2019-01-25
AU2019264555B2 (en) 2020-12-17
JP6496689B2 (ja) 2019-04-03

Similar Documents

Publication Publication Date Title
AR088535A1 (es) Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)
AR102492A1 (es) Cromanos sustituidos y métodos para su uso
AR124117A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR111242A1 (es) Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak
AR098872A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR106806A1 (es) Inhibidores triazol de acc y usos de los mismos
AR090587A1 (es) Compuestos triciclicos sustituidos con actividad hacia los receptores ep1
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR099995A1 (es) Piridilamidinas fungicidas
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094735A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR110753A1 (es) Inhibidores selectivos de jak1
AR092288A1 (es) Ligandos del receptor ep1
AR100714A1 (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
AR104555A1 (es) SULFONAS TRICÍCLICAS COMO MODULARES DE RORg
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR110001A1 (es) Derivados heteroarilo bicíclicos
AR101359A1 (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo
AR097138A1 (es) Compuestos plaguicidas
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2

Legal Events

Date Code Title Description
FG Grant, registration